Enrollment Closed: What Moleculin’s MIRACLE Trial Teaches About AML Site Execution
Moleculin closed Part A enrollment at 89 subjects in its pivotal AML MIRACLE trial. Here's what site directors and...
When the Primary Endpoint Moves After 283 Patients Are Already In
A mid-trial primary outcome amendment in a thrombectomy study reveals the operational chain reaction sites and sponsor clinops teams...
When You Change the Endpoint at Month 12: What CHOICE-2 Got Right About Amendment Governance
CHOICE-2 changed its primary endpoint after 283 enrollments with no interim data released. Here's what that timeline reveals about...
When the Primary Endpoint Changes Mid-Trial: The Amendment Playbook Sponsors Get Wrong
An intra-arterial alteplase trial changed its primary outcome at month 12 after 283 enrollments. Here's the clinops reality of...
The Protocol-Only Coverage Analysis: What a Site Can Defend Before the Budget Arrives
A protocol-scoped MCA is a real deliverable, but it has hard limits. Here is what you can and cannot...
What Radial’s 27-Site Brain Medicine Network Actually Means for EEG Endpoint Standardization
Radial's FDA-cleared Evoke EEG integration across 27 brain medicine clinics tests whether distributed neuroimaging endpoints can survive real-world site…
The Screen Failure You Can Prevent Before the Patient Leaves Home
Mayo Test Drive completed at 97.5% across MCI, mild, and moderate dementia patients, here's what that means for Alzheimer's...
“Hard to Reach” Is a Sponsor Operations Failure, Not a Population Problem
The Lancet calls out "hard to reach" as a stigmatizing label. For clinical ops, it's a site selection failure...
Another AI Clinical Data Platform Just Launched. Here’s What Sponsors Actually Need to Ask Before They Sign.
nPhase's AI clinical data platform promises smarter trial design, but before sponsors add another vendor, the activation-cycle math deserves...
A 25% Sample Size Cut Sounds Like a Win, Until You See the Amendment Queue
CONSONANCE's digitally enhanced MS endpoint cut required sample size 24.9%. Here's what that number costs in protocol amendments, IRB...